Bluefin Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bluefin Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-350,200	Closed	-$114K	–	761
2022 Q1	$114K	Buy	350,200 +188,800	+117%	+$17.4M	0.01%	395
2021 Q4	$1.47M	Sell	161,400 -138,600	-46%	-$16.7M	0.1%	160
2021 Q3	$1.92M	Buy	+300,000	New	+$38.6M	0.19%	93
2020 Q2	–	Sell	-351,300	Closed	-$1.11M	–	486
2020 Q1	$1.11M	Buy	351,300 +80,600	+30%	+$7.14M	0.14%	115
2019 Q4	$159K	Buy	270,700 +135,700	+101%	+$11.7M	0.01%	393
2019 Q3	$765K	Buy	+135,000	New	+$11.2M	0.11%	137
2019 Q2	–	Sell	-100,000	Closed	-$146K	–	481
2019 Q1	$146K	Sell	100,000 -393,800	-80%	-$33.5M	0.02%	237
2018 Q4	$1.2M	Buy	493,800 +3,500	+0.7%	+$282K	0.12%	99
2018 Q3	$500K	Buy	490,300 +390,300	+390%	+$37.8M	0.05%	228
2018 Q2	$353K	Sell	100,000 -128,500	-56%	-$11.8M	0.03%	237
2018 Q1	$448K	Buy	+228,500	New	+$20.9M	0.03%	207
2014 Q2	–	Sell	-1,185	Closed	-$700K	–	802
2014 Q1	$700K	Buy	+1,185	New	+$60.7K	0.04%	276

Other funds holding XBI

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Bluefin Capital Management's XBI Position: Q1 2023 in Review

Bluefin Capital Management held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q1 2023 at 0 shares worth $978K. The position accounts for 0.12% of the portfolio, ranked #55.

Bluefin Capital Management first reported a position in XBI in Q1 2020 and has held it in 4 quarters since. The position peaked at $29.5M in Q3 2021. 713 funds tracked by Wall St. Rank hold XBI as of Q1 2023.

Bluefin Capital Management held 0 shares of State Street SPDR S&P Biotech ETF worth $978K as of Q1 2023.
Bluefin Capital Management left its State Street SPDR S&P Biotech ETF share count unchanged in Q1 2023.
State Street SPDR S&P Biotech ETF made up 0.12% of Bluefin Capital Management's portfolio in Q1 2023, its #55 holding.
Bluefin Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2020 and has held it in 4 quarters since.
Bluefin Capital Management's State Street SPDR S&P Biotech ETF position peaked at $29.5M in Q3 2021.
713 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2023.

Based on Bluefin Capital Management's 13F filing for Q1 2023, filed 15 May 2023.